Division of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA, 90059, USA.
David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Cell Commun Signal. 2020 May 29;18(1):82. doi: 10.1186/s12964-020-00589-8.
Chemokines are a family of small cytokines, which guide a variety of immune/inflammatory cells to the site of tumor in tumorigenesis. A dysregulated expression of chemokines is implicated in different types of cancer including prostate cancer. The progression and metastasis of prostate cancer involve a complex network of chemokines that regulate the recruitment and trafficking of immune cells. The chemokine CCL2 and its main receptor CCR2 have been receiving particular interest on their roles in cancer pathogenesis. The up-regulation of CCL2/CCR2 and varied immune conditions in prostate cancer, are associated with cancer advancement, metastasis, and relapse. Here we reviewed recent findings, which link CCL2/CCR2 to the inflammation and cancer pathogenesis, and discussed the therapeutic potential of CCL2/CCR2 axis in cancer treatment based on results from our group and other investigators, with a major focus on prostate cancer. Video Abstract.
趋化因子是一类小分子细胞因子，可引导多种免疫/炎症细胞向肿瘤发生部位迁移。趋化因子表达失调与多种癌症有关，包括前列腺癌。前列腺癌的进展和转移涉及调节免疫细胞募集和迁移的趋化因子的复杂网络。趋化因子 CCL2 及其主要受体 CCR2 在癌症发病机制中的作用受到特别关注。CCL2/CCR2 的上调和前列腺癌中的各种免疫状态与癌症进展、转移和复发有关。在这里，我们综述了最近的研究结果，这些结果将 CCL2/CCR2 与炎症和癌症发病机制联系起来，并根据我们小组和其他研究人员的结果讨论了 CCL2/CCR2 轴在癌症治疗中的治疗潜力，主要集中在前列腺癌上。视频摘要。
